Multiple frequent recurrences in superficial transitional cell carcinoma of the bladder: Is survival compromised by a conservative management strategy?

British Journal of Urology

Volumn 79, Issue 5, 1997, Pages 726-730

  Hrouda, D ^a,b,c   Ogden, C ^a   Morris, S B ^a   Wanendeya, N ^a   Fisher, C ^a   Woodhouse, C R J ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Bladder neoplasms; Prognosis; Recurrence; Transitional cell carcinoma

Indexed keywords

BCG VACCINE;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONSERVATIVE TREATMENT; ENDOSCOPIC SURGERY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0031399033     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00118.x     Document Type: Article

References (15)

1. England HR, Paris AM, Blandy JP. The correlation of T1 bladder tumour history with prognosis and follow-up requirements. Br J Urol 1981; 53: 593-7
2. Hudson MA. When intravesical measures fail. Indications for cystectomy in superficial disease. Urol Clin North Am 1992; 19: 601-9
3. Pocock RD. Ponder BAJ, O'Sullivan JP, Ibrahim SK, Easton DF, Shearer RJ. Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report. Br J Urol 1982; 54: 711-5
4. Kaubisch S, Lum BL, Reese J, Freiha F, Torti FM. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991; 146: 28-31
5. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 22-9
6. Holmang S. Hedelin H, Anderstrom C. Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153: 1823-6; discussion 1826-7
7. Parmar MK, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989; 142: 284-8
8. Reading J, Hall RR, Parmar MK. The application of a prognostic factor analysis for Ta. T1 bladder cancer in routine urological practice. Br J Urol 1995; 75: 604-7
9. Morris SB, Shearer RJ, Gordon EM, Woodhouse CR. Superficial bladder cancer: timing of check cystoscopies in the first year. Br J Urol 1993; 72: 446-8
10. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150: 60-4
11. Oldbring J, Glifberg I, Mikulowski P, Hellsten S. Carcinoma of the renal pelvis and ureter following bladder carcinoma: frequency, risk factors and clinico-pathological findings. J Urol 1989; 141: 1311-3
12. Matthews PN, Madden M, Bidgood KA, Fisher C. The clinicopathological features of metastatic superficial papillary bladder cancer. J Urol 1984; 132: 904-6
13. Sanchez de la Muela P, Rosell D, Aguera L et al. Superficial bladder cancer: survival and prognostic factors. Eur Urol 1991; 20: 184-91
14. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995; 153: 1444-50
15. Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995; 13: 1404-8